Key Performance Indicators of Clinical Trials in JapanImplications for Reducing the Drug Lag

被引：0

作者：

Michinori Terada

Mamoru Narukawa

Masahiro Takeuchi

机构：

[1] Kitasato University,Department of Pharmaceutical Medicines, Graduate School of Pharmaceutical Sciences

[2] Clinical Research,Tokyo Laboratories

[3] Pfizer Global R&D,undefined

来源：

Pharmaceutical Medicine | 2009年 / 23卷 / 5-6期

关键词：

Azithromycin; Recruitment Rate; Project Assistant; Source Data Verification; Investigational Review Board;

D O I：

10.1007/BF03256786

中图分类号：

学科分类号：

摘要：

Background: In Japan, the launch of new drugs is often delayed compared with other major regions, including the US and European countries. This so-called ‘drug lag’ is a significant problem because patients are being denied access to new and potentially life-saving therapies.

引用

页码：305 / 308

页数：3